<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

<i>APC</i> and <i>TP53</i> Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

Recently, it was suggested that consensus molecular subtyping (CMS) may aide in predicting response to EGFR inhibitor (cetuximab) therapies. We recently identified that <i>APC</i> and <i>TP53</i> as two tumor suppressor genes, when mutated, may enhance cetuximab sensitivity a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ramya Thota, Mingli Yang, Lance Pflieger, Michael J. Schell, Malini Rajan, Thomas B. Davis, Heiman Wang, Angela Presson, Warren Jack Pledger, Timothy J. Yeatman
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
colorectal cancer
<i>APC</i>
<i>TP53</i>
mutations
CMS classification
EGFR inhibitors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/83b5ca18ff454dabb1beb852018f41e2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/83b5ca18ff454dabb1beb852018f41e2

Documents similaires